Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy, but this may soon change. A large Phase III clinical trial designed in collaboration with...
BOSTON, Dec. 5, 2019 /PRNewswire/ — EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer’s Disease...
Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis (IPF), will start in the coming weeks, Genkyotex announced in a progress report. Following approval by the U.S. Food and Drug...
First NIH-funded clinical trial in the US using umbilical cord derived mesenchymal stem cells for the treatment of patients with new onset type 1 diabetes Type 1 diabetes (T1D) is a chronic condition in which the body’s own immune system attacks and destroys...
SYDNEY–(BUSINESS WIRE)–NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced that NeuCeptin, a biosimilar candidate of...
BOSTON–(BUSINESS WIRE)– Cerevance a clinical stage biopharmaceutical company advancing new medicines for brain diseases, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a...
Email
Text